To further validate the role of the epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK)/matrix matalloproteinases 2 (MMP-2) activation in RNF128-induced metastasis, we analyzed the impact of introducing gefitinib (an inhibitor of EGFR), PD98059 (an inhibitor of MEK/ERK), and MMP-2 inhibitor into ESCC cells with stably overexpressed RNF128. This evidence concerns the gene MAP2K7 and esophageal squamous cell carcinoma.